BioCentriq to Partner with Kytopen for Cell Therapy Manufacturing
The companies will work together to determine the impact on autologous and allogeneic cell therapies by combining Kytopen’s proprietary Flowfect technology for non-viral cell engineering with other steps in the manufacturing process.
BioCentriq, a US-based gene therapy development and manufacturing center, announced on March 23, 2021 that it has entered into a partnership with Kytopen, a startup spun out of the Massachusetts Institute of Technology.
Under the terms of the agreement, the companies will work together to determine the impact on autologous and allogeneic cell therapies by combining Kytopen’s proprietary Flowfect technology for non-viral cell engineering with other steps in the manufacturing process, BioCentriq said in a company press release.
“The Flowfect platform is a transformative solution that eliminates the complexity of gene delivery for cell engineering and links discovery, development and manufacturing in one flexible scalable solution,” said Paulo A. Garcia, PhD, CEO and co-founder of Kytopen, in the press release. “Our goal is to enable simple and efficient non-viral manufacturing of cell therapies in days versus weeks to help patients; our partnership with BioCentriq accelerates that goal.”
“Our mission at BioCentriq is to work with innovative industry partners like Kytopen to advance the production and manufacturing of cell and gene therapies, making them accessible and affordable for the patients who so desperately need them” added Haro Hartounian, PhD, senior vice-president, general manager, BioCentriq, in the press release. “This partnership aligns perfectly with that mission.”
Source: BioCentriq
